

# W23: Transitioning Care; The Evolving care of women with

congenital genitourinary anomalies

Workshop Chair: Margaret Mueller, United States 29 August 2018 16:00 - 17:30

Start	End	Торіс	Speakers
16:00	16:15	Introduction to Transitioning care for women with Congenital GU anomalies	Margaret Mueller MD
16:15	16:30	Surgical management of complex GU anomalies	Margaret Mueller
16:30	16:50	Sexual health concerns with GU anomalies	Maureen Sheetz APN, WHNP-BC
16:50	17:10	Fertility and Reproductive Potential with GU anomalies	Lia Bernardi MD
17:10	17:30	Pelvic Floor Disorders in women with GU anomalies	Kimberly Kenton MD, MS

# Aims of Workshop

1. Describe common congenital genitourinary (GU) anomalies and their effects in women during different stages of life (adolescence, reproductive years, perimenopause/menopausal years).

2. Describe the medical and surgical management of GU anomalies and the associated sequelae of these interventions.

3. Uncover the gaps in care for women with GU anomalies, and strategies to maintain adequate care in this population.

# Learning Objectives

1. Define the need and objectives of a "transitions clinic" for women with congenital GU anomalies and Identify types of GU anomalies, with which women are diagnosed, which might benefit from a transitions clinic.

- 2. Illustrate the fertility, pelvic floor and sexual health concerns and needs of women with congenital genitourinary anomalies.
- 3. Demonstrate integrated and comprehensive management for women with congenital genitourinary anomalies.

# Learning Outcomes

After attending this course the participant will be able to identify the sequelae of common genitourinary anomalies as well as strategies for managing these chronic conditions.

# **Target Audience**

Urogynaecologists; urologists; female pelvic medicine and reconstructive surgery specialists; trainees (residents/fellows).

# Advanced/Basic

Advanced

# **Conditions for Learning**

Learners will be exposed to different speakers who will convey their information through powerpoint presentations.

# Suggested Learning before Workshop Attendance

R.M. Laterza et al. / European Journal of Obstetrics & Gynecology and Reproductive Biology 159 (2011) 26–34 MA Hall-Craggs et al./Journal of Pediatric Urology (3013) 9, 27-32 PK Heinonen / European Journal of Obstetrics & Gynecology and Reproductive Biology 206 (2016) 141-46

# **Suggested Reading**

R Chan, UROLOGY 84: 1544e1548, 2014 H Stephany, UROLOGY 85:959e963, 2015 K.A.McCracken,M.E.Fallat, Seminars in Pediatric Surgery 24(2015)88–92 S.M. Lambert / Seminars in Pediatric Surgery 24 (2015) 73–78 Khavari R, Journal of Urology 194 (2015) 1654-8 PMID 26210885 V Trofimenko, Current Opinion Urology 26 (2016) 357-62

# Margaret Mueller, MD

This workshop will focus on the evolving care of women with congenital GU anomalies. First, we will highlight the idea of "transitioning care" for these women. Specifically, the transition requires a seamless and integrated "hand-off" between pediatric providers and specialized adult providers well versed in anticipating future needs of these adolescents and young women with respect to the known sequelae- pelvic floor disorders, sexual dysfunction and fertility challenges. Urogynecologists

are well-suited to orchestrate this transition as surgeons and pelvic health specialists. Additionally, sexual health providers, reproductive endocrinologists, physical therapists are crucial to the interdisciplinary management of these young women.

Briefly, we will illustrate both common and uncommon GU anomalies and their associated specific sequelae as well as their initial surgical management. Attention will be paid to the pelvic reconstructive techniques including vaginoplasty.

# Sexual health concerns with GU anomalies Maureen Sheetz APN

Sexual health is of utmost concern to practitioners caring for adolescents and young women with GU anomalies. Often times this is overlooked, and these women are not afforded the screening for and prevention of sexual health disorders. Moreover, women whom have undergone reconstructive procedures as children, face unique challenges with respect to sexual function as adolescents and adults. The timing and approach to reconstructive vaginal surgery (vaginoplasty) is extremely important and an issue of evolving complexity. Finally, issues related to decreased sexual satisfaction relating to pain, embarrassment and fear are present in this population. We will focus on the appropriate evaluation and management of sexual dysfunction in women with GU anomalies.

# <u>Fertility and Reproductive Potential with GU anomalies</u> Lia Bernardi MD

Gentiourinary anomalies can impact the ability of a woman to conceive as well as her capacity to carry a pregnancy to term. In this workshop we will review how genitourinary anomalies can affect fertility and will discuss treatment options aimed at optimizing pregnancy outcomes. Specifically, we will examine the most common uterine malformations including septate, bicornuate, unicornuate and didelphys uterus, discuss their impact on fertility and pregnancy outcomes and explain surgical treatments that may increase likelihood of reproductive success. We will describe how congenital adrenal hyperplasia can make achieving a pregnancy more challenging and will discuss options that can optimize an individual's ability to successfully conceive. In addition, we will discuss Mayer-Rokitansky-Kuster-Hauser syndrome and explain options for family building in the setting of müllerian agenesis. We will also review the latest outcome data on uterine transplant in this patient population.

# Pelvic Floor Disorders in women with GU anomalies

# Kimberly Kenton MD, MS

Pelvic floor disorders including prolapse and incontinence are very common in this population. Given the presence of anomalies and the associated surgical corrections, managing PFDs in this population is complex and can be challenging. We will focus on the evaluation and management of prolapse and incontinence in women with different GU anomalies. Specifically, we will examine the challenges of surgical management of prolapse and incontinence within this population, and the anticipated outcomes.



















































































































Initial bladder closure of the cloacal errelated risk factors and keys to succes	kstrophy con s	mplex: O	utcome	۲	
Bhavik B. Shah **, Heather Di Carlo <sup>b</sup> , Seth D. Go Eric Z. Massanyi <sup>b</sup> , Adam Kern <sup>b</sup> , June Koshy <sup>d</sup> , Pi 100 patients with CE and primary closu	oldstein °, Philli aul Sponseller ° Ire	p M. Pierora , John P. Ge	nzio <sup>b</sup> , Brian M. I arhart <sup>b</sup>	nouye <sup>b</sup> ,	
<ul> <li>26 patients with failed closure</li> </ul>	compared t	to 34 with	n successful c	losure	
Table 2					
Table 2 Univariate logistic analysis of variables affe	ecting primary	closure failu	ire.		
Table 2 Univariate logistic analysis of variables affe Variable	ecting primary Odds ratio	closure failu p-value	ıre. 95% CI		
Table 2         Univariate logistic analysis of variables affective         Variable         46XY Genotype	ecting primary Odds ratio 1.030	closure failu p-value 0.956	95% CI 0.353-3.007	-	
Table 2         Univariate logistic analysis of variables aff         Variable         46XY Genotype         Pre-closure diastasis (centimeters)	Odds ratio	closure failu p-value 0.956 0.004	95% CI 0.353-3.007 1.363-5.099	-	
Table 2           Univariate logistic analysis of variables aff           Variable           46XY Genotype           Pre-closure diastasis (centimeters)           Delay between omphalocele           closure and primary bladder closure	Odds ratio 1.030 2.636 0.024	closure failu p-value 0.956 0.004 0.001	95% CI 0.353-3.007 1.363-5.099 0.003-0.209	-	
Table 2 Univariate logistic analysis of variables affi Variable 46XY Genotype Prc-closure diastasis (centimeters) Delay between omphalencie closure and primary bladder closure Age at closure (months)	Odds ratio 1.030 2.636 0.024 0.894	closure failu p-value 0.956 0.004 0.001 0.002	95% CI 0.353-3.007 1.363-5.099 0.003-0.209 0.833-0.960	-	
Table 2           Univariate logistic analysis of variables aff           Variable           46XY Genotype           Pre-closure diatasis (centimeters)           Delay between omphalocele           closure and primary bladder closure           Age at closure (norths)           Osteotomy	ecting primary Odds ratio 1.030 2.636 0.024 0.894 0.095	closure failu p-value 0.956 0.004 0.001 0.002 <0.001	95% CI 0.353-3.007 1.363-5.099 0.003-0.209 0.833-0.960 0.028-0.320	-	
Table 2 Univariate logistic analysis of variables affi Variable 46XY Genotype Prc-closure diastasis (centimeters) Delay between omphalocide closure and primary bladder closure Age at closure (months) Osteotomy External fixator	ecting primary Odds ratio 1.030 2.636 0.024 0.894 0.095 0.024	closure failu p-value 0.956 0.004 0.001 0.002 <0.001 0.001	95% CI 0.353-3.007 1.363-5.099 0.003-0.209 0.833-0.960 0.028-0.320 0.003-0.203	-	
Table 2 Univariate logistic analysis of variables affi Variable 46XY Genotype Pre-dosure diastasis (centineters) Dely between omphablecele Age at closure (montbadder closure Age at closure (montbadder closure Dely between osteoromy and closure"	ecting primary Odds ratio 1.030 2.636 0.024 0.894 0.095 0.024 0.033	closure failu p-value 0.956 0.004 0.001 0.002 <0.001 0.001 0.005	95% CI 0.353-3.007 1.363-5.099 0.003-0.209 0.833-0.960 0.028-0.320 0.003-0.203 0.003-0.203	-	







# Are they ready

https://youngwomenshealth.org/2014/07/11/mrkh-transitioning-to-adult-gynecology-care/

- I can explain MRKH (and any other medical conditions I have) to my GYN and medical providers. (If not, it's very helpful to provide your GYN and other medical providers with a copy of the MRKH guide for health care providers.)
- · I know the names and phone numbers of all of my health care providers
- I ask questions during my GYN and other medical appointments.
- I know what medications I take and I have a list that I bring to my GYN and medical appointments. I tell my providers when I no longer take certain medicine(s) and when I start a new medicine(s).
- I feel comfortable responding to questions my gynecologist and other medical providers asks.
- I am able to schedule my GYN and other medical appointments by myself and I have a way of keeping track of them so I don't miss appointments.
- I know about my health insurance coverage and how much my co-pay is for different medical services.
- I know where and how to obtain a copy of my medical records.
  I am able to get to my GYN and other medical appointments by myself.
- I know where to get my prescriptions filled, and have called the pharmacy when I've had

NU

questions or needed refills.

Northwestern Medicine 

 Transitioning care

 What do you need to KNOW?

 • Detailed description of surgical and medical history

 • Fertility and pregnancy potential/ capability

 • Sexual health/function

 • Risks for other quality of life disorders (prolapse)

 • Coordination and management of chronic conditions (incontinence, voiding dysfunction)

# Take home points

- GU anomalies are common and affect sexual health, fertility and the pelvic floor
- Care involves a multidisciplinary approach focusing on transition from pediatric to adult provider
- Anticipate the obstacles that these women face

Northwestern Medicine















Northwestern Medicine'



# Cloacal Exstrophy Northwestern's Experience \* 23 yo with cloacal exstrophy spontaneously conceives - Pregnancy complications \* Prolapse \* Northwestern's Experience \* Cloacal Exstrophy Prolapse before and after reconstructive surgery \* Notputadmission for yea \* Hospitaladmission for YELP - Classical C/S at 34 wks \* Symptomatic POP continued post-partum - Pessary not able to manage patient's symptoms - Underwent abdominal sacral colpopexy

Northwestern Medicine

# Classic Bladder Exstrophy Continence

# Examining long-term outcomes of bladder exstrophy: a 20-year follow-up

Angela D. Gupta, Sameer K. Goel, Christopher R.J. Woodhouse\* and Dan Wood\* Department of Unicay, Johns Hopkins Medical Institutions, Baltimote, MD, USA and \*University College London Negatiais, Lindon, UK BUI International © 2013 BJU International BUI Int 2014; 113: 137–141

61 patients were identified (>20 years of age, men and women)

- All had undergone additional surgeries after their original reconstructive procedures
- 21 patients responded to this survey (15 men, 6 women)
  - 20 performed CISC
  - 1 was continent and self voiding
  - 13 patients completely continent, no leakage episodes on ICIQ

Northwestern Medicine'

# Cloacal Exstrophy

Continence

Northwestern Medicine

# Clinical Outcome of Cloacal Exstrophy, Current Status, and a Change in Surgical Management

Rob van Vliet<sup>1</sup> Luc A. J. Roelofs<sup>2</sup> Roxana Rassouli-Kirchmeier<sup>1</sup> Robert P. E. de Gier<sup>2</sup> Hedi L. Claahsen-van der Grinten<sup>3</sup> Chris Verhaak<sup>4</sup> Allard J. Hosman<sup>5</sup> Catharina C. M. Beerendonk<sup>6</sup> Erik J. van Lindert<sup>7</sup> Michel A. A. P. Willemsen<sup>8</sup> Marc H. W. A. Wijnen<sup>1</sup> Wout F. J. Feitz<sup>2</sup> Ivo de Blaauw<sup>1</sup>

- 14 patients identified with CE (5 women)
  - Initial bladder closure attempted in 13 cases, 9 initial failures
  - 5 underwent bladder neck reconstruction, 10 underwent later
  - augmentation cystoplasty or diversion
  - 2 remain continent

Morthwestern Medicine'









# Prolapse of the Neovagina

Sigmoid neovagina: primary repairs

- Case report: A 41 year old with MRKH who underwent sigmoid neovagina creation at age 17 presented with stage 3 apical prolapse and a "bearing down" sensation. She underwent laparoscopic "nerve-sparing" suspension of the vagina with a hybrid monocril / polypropylene mesh and polyester with polyglactin suture to the anterior longitudinal ligament at L5.
- Case report: A 72 year old with MRKH who underwent sigmoid neovagina creation at age 21 presented with stage 4 apical prolapse. She underwent laparoscopic sacral colpopexy with polypropylene mesh and polyester suture.2

Northwestern Medicine'

nger V. I Pediatr Adolesc Gyn col 28 (2015) e153-e1 <sup>2</sup>Popov A. Int Urogynecol J (2016) 27:315–316

### Prolapse of the Neovagina Recurrences and their repairs • 28 year old with MRKH Self-dilated at age 19 and achieved intercourse - 8 years later: vaginal prolapse beyond the hymen repaired by a community urologist: Anterior and Posterior repair with AMS Elevate mesh Transobturator midurethral sline 1 year postoperatively: complete vault eversion, TVL 4 cm, scarring Staged repair: · Mesh removal followed by postoperative dilation • 8 months later: Abdominal sacral colpopexy with polypropylene mesh and absorbable suture Posterior vaginal extension using cadaveric dermis Postoperative vaginal dilation and vaginal estrogen for 3 months 6 months after surgery: excision / fulguration of posterior granulation tissue • 1 year follow up: – Aa, –3; Ba, –3; C, –5;Gh, 3.5; Pb, 3; TVL, 7.5; Ap, –2; and Bp, –2

Toidze TV. Female Pelvic Med Reconstr Surg 2015;21: e33-e3

Medicine'







# Herlyn-Werner-Wunderlich Syndrome

- 17 yo with a müllerian anomaly presents with pain and abnormal bulge in vagina when urinating
- PMH:
  - Uterine didelphyis –Right vaginal septum and associated hematocolpos, L solitary kidney
- PSH:
   2007-reportion of right transverse variable century
- 2007: resection of right transverse vaginal septum
  2011: repair of "anterior vaginal wall hernia"
- Ultimately required repair of vaginal wall defect with graft

Northwestern Medicine







# In summary...

- GU anomalies predispose women to POP and UI
- Knowledge of common reconstructive surgeries
- Operative reports
- In patients with Exstrophy-Epispadias Complex:
   POP may be best managed with sacral colpopexy after childbearing
   Bulking may improve urinary incontinence after BNR
- MRKS: TV mesh may lead to failure and future revision surgeries
- Herlyn-Werner-Wunderlich Syndrome:
- Complications of transverse septum resection: POP

Morthwestern Medicine'



































Roman Rouzier <sup>c</sup>					
Table 2					
Domain	Nonsurgical group (n=20)	Surgical group (n=20)	р		
Desire	4.5±1.0	$4.6 \pm 0.8$	0.5		
Arousal	$4.4 \pm 1.6$	$4.3 \pm 1.7$	0.7		
Lubrication	$4.2 \pm 2.0$	$4.3 \pm 1.8$	0.8		
Orgasm	$4.0 \pm 1.8$	$3.8 \pm 1.9$	0.6		
Satisfaction	$4.7 \pm 1.6$	$4.7 \pm 1.7$	1.0		
Comfort	$3.4 \pm 1.9$	$3.6 \pm 2.1$	0.6		
Total FSFI score	$25.3 \pm 7.5$	$25.3 \pm 8.0$	1.0		
Values are given as n	nean $\pm$ standard deviation (9	5% confidence interval).			



TADI E 7							
Vaginal length and	sexual quality of li	fe according to	surgical tech	iniques			
Surgical technique	Vag	inal length, cm		FSFI score			SDS-R scor
Vecchietti, n = 6	11.	3 [11-12]		30.2 [18.7-	-34.8]		3 [10-39]
Sigmoid, n = 57	11	[6-15]		25.7 [2.8-	34]		20.5 [0-50]
McIndoe, n = 5	12	[11-13]		28.4 [8.4-	34.8]		1 [0-52]
Davidov, n = 8	8.	5 [7-11]		23.0 [4.8-	33.6]		8 [0-41]
Dupuytren, n = 8	9.	3 [8-12]		27.9 [15.3-	-34]		4.5 [1-32]
Ρ	ر	002		.28			49
F3DS-R, Fernie Sonai Detres Cheikheinsl et al. Quality of i	i Scale-Hevlenet; FSFI, Fernale S life in MRKH: surgery vs dila	leozal Function Index. tion reginaplicity. Am	l Obstat Gynecol 2011	R.			
7309-R Fernale Social Detroit Chekhedend et al. Quality of I TABLE 8 Female Sexual Fun	i Stale-Reviset, FSR1, Fensie S lije in MRKH: sangery vs dila ction Index scores	ierual Fanction Index. ricen waginoplisity. Am , according to ty	Point Gynecol 2010	ment			
ADD-R, Ferser Social Define Cleckholand et al. Quality of i TABLE 8 Female Sexual Fun Type of management	State Perviset; FUR1, Fernale 5 Spin MRX21: sargery vs dile ction Index scores Global FSFI score	Ierual Function Index. tion regimplicity. Am . according to ty Desire	Distr Gynecol 2000	ment	Orgasm	Satisfaction	Pain
ABDE A Ferrare Social Detroit Cheldwised et al. Quellity of i TABLE 8 Female Sexual Fun Type of management All patients	Sole-Reviset, F3R, Fende S Se in MBX2F: segrey vs dila ction Index scores Global FSR score 26 [2.6–34.80]	Ieraal Function Index. tion regineplasty. Am . according to ty Desire 4.2 [1.2-6]	pe of manage Excitation 4.5 (0-6)	ment Lubrication 4.8 (0-6)	Orgasm 4.4 [0-6]	Satisfaction 5.2 [0.8-6]	Pain 3.6 (0-6
TABLE 8 TABLE 8 Female Sexual Fun Type of management All patients Surgery (1) n = 84	Scan-Revise: F37, Fonds 1 (c) in M9037: segmy vs dila ction Index scores Global FSFI score 26 (2.6–34.80) 26 (2.8–34.8)	according to ty Desire 4.2 [1.2-6] 4.2 [1.2-6]	pe of manage Excitation 4.5 (0-6) 4.5 (0-6)	ment Lubrication 4.8 [0-6] 4.8 [0-6]	Orgasm 4.4 [0-6] 4.2 [0-6]	Satisfaction 5.2 [0.8-6] 4.8 [0.8-6]	Pain 3.6 (0-6 3.2 (0-6
TABLE 8 TABLE 8 Female Sexual Fun Type of management All patients Surgery (1) n = 84 Dilation (2) n = 25	Scan-Reviset: F37, Fende 1 (c) in M0037: sergery vs dila ction Index scores Global FSFI score 26 (2.6–34.80) 26 (2.8–34.8) 24,7 (2.6–34.4)	according to ty Desire 4.2 [1.2-6] 4.2 [1.2-6] 4.5 [1.8-5.4]	04sar Gynecol 200 pe of manage Excitation 4.5 [0-6] 4.5 [0-6] 4.4 [0-5.7]	ment Lubrication 4.8 [0-6] 4.8 [0-6] 4.7 [0-6]	Orgasm 4.4 [0-6] 4.2 [0-6] 3.6 [0-6]	Satisfaction 5.2 [0.8-6] 4.8 [0.8-6] 4.8 [0.8-6]	Pain 3.6 [0-6 3.2 [0-6 3.6 [0-6
TABLE 8 Female Sexual Fun Type of management All patients Surgery (1) n = 84 Dilation (2) n = 25 Intercourse (3) n = 18	Isaa-Revect. 797. Forsis 5 (k in MRX7): magny vs dia Global FSFI score 26 [2.6–34.80] 26 [2.8–34.8] 24.7 [2.6–34.4] 30.2 [7.8–34.8]	Incud Function Index. Inter regimplicity. Am , Desire 4.2 [1.2–6] 4.2 [1.2–6] 4.5 [1.8–5.4] 4.5 [3–6]	0haar Gynecol 200 pe of manage Excitation 4.5 [0-6] 4.5 [0-6] 4.4 [0-5.7] 4.5 [0-6]	ment Lubrication 4.8 [0-6] 4.8 [0-6] 4.7 [0-6] 4.7 [0-6]	0rgasm 4.4 [0-6] 4.2 [0-6] 3.6 [0-6] 4.8 [0-6]	Satisfaction 5.2 [0.8-6] 4.8 [0.8-6] 4.8 [0.8-6] 6 [1.2-6]	Pain 3.6 (0-6 3.2 (0-6 3.6 (0-6 3.6 (0-6 5.4 (0-6
TABLE 8 Female Sexual Fun Type of management All patients Surgery (1) n = 84 Dilation (2) n = 25 Intercourse (3) n = 18	State-Hermit, 1/31, Fermit 1           Vic in ABXR: surgery on dila           Global FSR score           Silobal FSR score           28 [2.6-34.80]           26 [2.6-34.80]           26 [2.6-34.8]           24.7 [2.6-34.8]           30.2 [7.8-34.8]           P = .044"	Interference of the second se	Obser Gynecol 2010           pe of manage           Excitation           4.5 [0-6]           4.4 [0-5.7]           4.5 [0-6]           4.5 [0-6]           4.5 [0-6]	Lubrication 4.8 [0-6] 4.7 [0-6] 4.7 [0-6] 4.7 [0-6] β = 57	0rgasm 4.4 [0-6] 4.2 [0-6] 3.6 [0-6] 4.8 [0-6] β= 33	Satisfaction 5.2 [0.8-6] 4.8 [0.8-6] 6 [1.2-6] <b>F</b> = .04 <sup>2</sup>	Pain 3.6 (0-6 3.2 (0-6 3.6 (0-6 5.4 (0-6 P = 22













Cloacal Exstrophy	Take home points	
<ul> <li>Sexual function <ul> <li>4/6 women had further genital surgery</li> <li>3/5 women (&gt;18 years) had intercourse</li> <li>2 reported sexual satisfaction</li> <li>1 discontinued sexual activity 2/2 uterine prolapse</li> <li>2 patients reported that they were not sexually active due to the appearance of their genitalia</li> </ul> </li> </ul>	<ul> <li>Women in this population are sexual and can have a healthy functional sexual relationship</li> <li>Many women have barriers to satisfactory sexual function</li> <li>Must address this proactively</li> <li>Remember birth control or STI prevention if indicated!</li> </ul>	
Northwestern Mercone	Northwestern	









Anomaly	Conception rate	First-trimester miscarriage	Second-trimester miscarriage	Preterm labor	Malpresentatio at delivery
Arcuate uterus	1.03	1.35	2.39	1.53	2.53
	(0.94 - 1.12)	(0.81 - 2.26)	(1.33-4.27)**	(0.70 - 3.34)	$(1.54 - 4.18)^{**}$
Canalization defects					
Subseptate	0.80	2.94	1.86	2.01	5.29
	(0.57 - 1.11)	(1.90-4.54)***	(0.56-6.22)	(1.16-3.51)*	(1.89-14.86)*
Septate	0.93	2.3/	5./4	2.30	6.15
	(0, 75 = 1, 17)	(1.64-3.43)***	(1.5/-8.91)**	(1.46-3.62)***	(3.96-9.53)**
All	0.86	2.89	(0.74-6.65)	2.14	6.24
	(0.77=0.96)*	(2.02-4.14)***	(0.74 - 6.65)	(1.48-3.11)***	(4.05-9.62)**
Unification defects					
Bicornuate	0.86	3.40	2.32	2.55	5.38
	(0.61 - 1.21)	(1.18 - 9.76)*	(1.05-5.15)*	(1.57-4.17)***	(3.15-9.19)**
Didelphys	0.9	1.10	1.39	3.58	3.70
	(0.79-1.04)	(0.21-5.66)	(0.44-4.41)	(2.00-6.40)***	(2.04-6.70)**
Unicornuate	0.74	2.15	2.22	3.47	2.74
	(0.39-1.41)	(1.03-4.4/)*	(0.53-9.19)	(1.94-6.22)***	(1.30-5.77)**
All	0.8/	2.36	1.94	2.9/	3.8/
	(0.68-1.11)	(0.89-7.38)	(0.92-4.09)	(2.08-4.23)	(2.42-6.18)

Anomaly	Conception rate	First-trimester miscarriage	Second-trimester miscarriage	Preterm labor	Malpresentation at delivery
Arcuate uterus	1.03	1.35	2.39	1.53	2.53
	(0.94 - 1.12)	(0.81 - 2.26)	$(1.33 - 4.27)^{**}$	(0.70 - 3.34)	$(1.54 - 4.18)^{***}$
Canalization defects					
Subseptate	0.80	2.94	1.86	2.01	5.29
6	(0.57-1.11)	(1.90-4.54)***	(0.56-6.22)	(1.16-3.51)*	(1.89-14.86)**
septate	(0.75-1.17)	(1 64-2 42)***	3./+ /1.67_9.01\##	2.30	(2.06-0.52)***
All	0.75=1.17)	2.89	2 22	2 14	6 24
	(0.77-0.96)*	(2.02-4.14)***	(0.74 - 6.65)	(1.48-3.11)***	(4.05-9.62)***
Unification defects			(	(	
Bicormunte	0.86	3.40	2 32	2.55	5.28
Dicormanc	(0.61 - 1.21)	(1.18-9.76)*	(1.05-5.15)*	(1.57-4.17)***	(3.15-9.19)***
Didelphys	0.9	1.10	1.39	3.58	3.70
	(0.79 - 1.04)	(0.21 - 5.66)	(0.44 - 4.41)	(2.00-6.40)***	$(2.04-6.70)^{***}$
Unicornuate	0.74	2.15	2.22	3.47	2.74
	(0.39 - 1.41)	(1.03-4.47)*	(0.53 - 9.19)	(1.94-6.22)***	(1.30-5.77)**
All	0.87	2.56	1.94	2.97	3.87
	(0.68 - 1.11)	(0.89 - 7.38)	(0.92 - 4.09)	(2.08-4.23)***	(2.42-6.18)***

Anomały	Conception rate	First-trimester miscarriage	Second-trimester miscarriage	Preterm labor	Malpresentation at delivery
Arcuate uterus	1.03	1.35	2.39	1.53	2.53
	(0.94 - 1.12)	(0.81 - 2.26)	$(1.33 - 4.27)^{**}$	(0.70 - 3.34)	$(1.54 - 4.18)^{***}$
Canalization defects					
Subseptate	0.80	2.94	1.86	2.01	5.29
	(0.57 - 1.11)	(1.90-4.54)***	(0.56-6.22)	$(1.16 - 3.51)^{\circ}$	(1.89-14.86)**
Septate	0.93	2.37	3.74	2.30	6.15
	(0.75 - 1.17)	(1.64-3.43)***	(1.57-8.91)**	(1.46-3.62)***	(3.96-9.53)***
All	0.86	2.89	4.66	2.14	6.24
	(0.77-0.96)*	(2.02-4.14)***	(0.74 - 6.65)	$(1.48 - 3.11)^{***}$	(4.05-9.62)***
Unification defects					
Bicornuate	0.86	3.40	2.32	2.55	5.38
	(0.61 - 1.21)	(1.18-9.76)*	$(1.05 - 5.15)^*$	(1.57-4.17)***	(3.15-9.19)***
Didelphys	0.9	1.10	1.39	3.58	3.70
	(0.79 - 1.04)	(0.21 - 5.66)	(0.44 - 4.41)	(2.00=6.40)***	(2.04-6.70)***
Unicornuate	0.74	2.15	2.22	3.47	2.74
	(0.39 - 1.41)	(1.03-4.47)*	(0.53 - 9.19)	(1.94-6.22)***	(1.30-5.77)**
All	0.87	2.56	1.94	2.97	3.87
	(0.68 - 1.11)	(0.89 - 7.38)	(0.92 - 4.09)	(2.08-4.23)***	(2.42-6.18)***

Northwestern Medicine

Anomaly	Conception rate	First-trimester miscarriage	Second-trimester miscarriage	Preterm labor	Malpresentatio at delivery
Arcuate uterus	1.03	1.35	2.39	1.53	2.53
	(0.94 - 1.12)	(0.81 - 2.26)	(1.33-4.27)**	(0.72 3.34)	(1.54-4.18)**
Canalization defects					
Subseptate	0.80	2.94	1.86	2.01	5.29
	(0.57 - 1.11)	(1.90-4.54)***	(0.56 - 6.22)	(1.16-3.51)*	(1.89-14.86)
Septate	0.93	2.37	3.74	2.30	6.15
	(0.75-1.17)	(1.64-3.43)***	(1.57-8.91)**	(1.46-3.62)***	(3.96-9.53)*
All	(0.77-0.96)*	(2.02-4.14)***	(0.74-6.65)	(1.48-3.11)***	(4.05-9.62)*
Unification defects				,,	
Bicornuate	0.86	3.40	2.32	2.55	5.38
	(0.61 - 1.21)	$(1.18 - 9.76)^*$	(1.05-5.15)*	(1.57-4.17)***	(3.15 - 9.19)*
Didelphys	0.9	1.10	1.39	3.58	3.70
	(0.79 - 1.04)	(0.21 - 5.66)	(0.44 - 4.41)	(2.00-6.40)***	$(2.04 - 6.70)^{**}$
Unicornuate	0.74	2.15	2.22	3.47	2.74
	(0.39 - 1.41)	(1.03-4.47)*	(0.53 - 9.19)	(1.94-6.22)***	(1.30-5.77)*
All	0.87	2.56	1.94	2.97	3.87
	(0.68 - 1.11)	(0.89 - 7.38)	(0.92 - 4.09)	2.08-4.23)	(2.42-6.18)*

































# Congenital Adrenal Hyperplasia: Preconception Counseling

- Classic CAH
- Carrier frequency 1:62
- Likelihood of having an affected child 1:120
- Non-classic CAH
- Carrier frequency 1:5-1:16
- Likelihood of having an affected child 1:32
- · Recommend screening partner for carrier status and can offer Preimplantation genetic testing of embryos if desired

# Northwestern Medicine'

# Congenital Adrenal Hyperplasia: Fertility Treatments

- Classic CAH → Nearly all require treatment to ovulate
- Ovulation using only steroid maintenance therapy
- May need additional corticosteroids to suppress adrenal progesterone production

### Non-Classic CAH

- Androgen excess frequently correctable with glucocorticoid treatment alone
- Ovulation induction with letrozole or clomiphene

Northwestern Medicine'



# **Earliest Attempts**

## • 1931

- Lili Elbe, a transgender woman, died from organ rejection 3 months after receiving a uterine transplant
- 2000
- Saudi Arabia. Transplantation of a uterus from a 46 yo hysterectomy patient to a 26 yo recipient
- Uterus functioned for 99 days and then was removed for
- thrombosis and uterine necrosis
- 2011
- First uterus transplant from a deceased donor was performed on Derva Sert in Turkey
- First pregnancy, however pregnancy ended in miscarriage

# Northwestern Medicine'







Northwestern Medicine'

### Summary

- · Congenital GU anomalies can have significant impacts on fertility and pregnancy outcomes
- Appropriate diagnosis can be achieved with 3D ultrasound +/- saline
- · Correction of a uterine septum can improve fertility and decrease miscarriage rates
- · Pregnancy is possible in women with CAH with steroid hormone replacement and/or ovulation induction
- Women with MRKH can have success with the use of IVF and a gestational surrogate. Investigation into experimental treatment with uterine transplant is ongoing.

Northwestern Medicine

# References

- Fritz M, Speroff L. Clinical Gynecologic Endocrinology. 2010
   Yen & Jaffe. Reproductive Endocrinology. 2019
- Viterine Septime, Aguideline: Practice Committee of the American Society of Reproductive Medicine
   Shuiqing M, Xuming B, Jinghe L. Pregnancy and its outcome in women with malformed uterus. Chin
   Med Sci J 2002;17:242-5
- Med Sci J 2002;17:24:25
   Maneschi F, Zupi E, Marconi D, Valli E, Romanini C, Mancuso S. Hysteroscopically detected asymptomatic multierian anomalies. Prevalence and Reproductive implications.
   Venetis CA, Papadopoulos SP, Campo R, Gordts S, Tarlatzis BC, Grimbizis GF, Clinical implications of congenital atterine anomalies: a meta-analysis of comparative studies. Repro Biomed Online 2014; 25:65:83
- 22003-03 Tonguic EA, Var T, Batioglu S, Hysteroscopic metroplasty in patients with a uterine septum and otherwise unexplained infertility. Int J Gynaecol Obst 2011; 113:128-30 Kupesic S, Kurjac A, Skenderovic S, Bjelos D. Screening for uterien abnormalities by three-dimentional ultrasound improve perindial outcome. J Perindal Med. 2002; 30: 9-17
- Tongue E-V, Var T, Vilma N, Baldigul S. Intrauterine device or estrogen treatment after hysteroscopic uterine septum resection. Int J Gynaecal Obset 2010; 109:226-9
   Reichmand, White P, New M, RosenwaksZ Fertility in patients with congenital adrenal hyperoplasia. Fertility and Steility; 2014;101(2):301-309

Northwestern Medicine

